Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20138718 | 0.91 | SMN1; SMN2 (0.34) | SMN1; SMN2 | |
| SCHEMBL20139332 | 0.84 | EPAS1 (0.40) | — | |
| SCHEMBL20154251 | 0.82 | SMN1; SMN2 (0.32) | PPARGSMN1; SMN2 | |
| SCHEMBL20138711 | 0.79 | KDM4E (0.39) | PPARGSMN1; SMN2 | |
| SCHEMBL20139093 | 0.75 | EPAS1 (0.38) | — | |
| SCHEMBL20142947 | 0.75 | DGAT1 (0.33) | — | |
| SCHEMBL20138678 | 0.72 | DGAT1 (0.32) | — | |
| SCHEMBL20138683 | 0.72 | — | — | |
| SCHEMBL20138791 | 0.71 | KDR (0.41) | PPARGSMN1; SMN2 | |
| SCHEMBL20138689 | 0.70 | EPAS1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109790149-B | Phenoxytriazoles | 豪夫迈·罗氏有限公司 | 2022-05-17 | — | — | CN | disclosed |
| US-11319314-B2 | Phenoxytriazoles | HOFFMANN-LA ROCHE INC. (US) | 2022-05-03 | — | — | US | disclosed |
| US-11319314-B2 | Phenoxytriazoles | HOFFMANN-LA ROCHE INC. (US) | 2022-05-03 | — | — | US | disclosed |
| US-20210309653-A1 | PHENOXYTRIAZOLES | HOFFMANN-LA ROCHE INC. (US) | 2021-10-07 | — | — | US | disclosed |
| US-20210309653-A1 | PHENOXYTRIAZOLES | HOFFMANN-LA ROCHE INC. (US) | 2021-10-07 | — | — | US | disclosed |
| EP-3538516-B1 | PHENOXYTRIAZOLES | HOFFMANN LA ROCHE (CH) | 2021-06-16 | — | — | EP | disclosed |
| EP-3538516-B1 | PHENOXYTRIAZOLES | HOFFMANN LA ROCHE (CH) | 2021-06-16 | — | — | EP | disclosed |
| EP-3538516-A1 | PHENOXYTRIAZOLES | F. Hoffmann-La Roche AG (CH) | 2019-09-18 | — | — | EP | disclosed |
| WO-2018087018-A1 | PHENOXYTRIAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2018-05-17 | — | — | WO | disclosed |
| WO-2018087018-A1 | PHENOXYTRIAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210309653-A1 | PHENOXYTRIAZOLES | HTT, PSEN1, APP | PPARG 2002/4885SMN1; SMN2 2236/4885 |
| US-11319314-B2 | Phenoxytriazoles | HTT, APP, PSEN1 | PPARG 1140/4885SMN1; SMN2 2639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.